Mark J. alles, former chairman and CEO of Xinji, joined the board of directors of deqi pharmaceutical

Shanghai and Philadelphia, January 8, 2020 / Meitong news agency / -- the board of directors of deqi pharmaceutical announced today that Mr mark J alles has been appointed as an independent director of the company, and the appointment will take effect from January 2, 2020 Mr mark J alles was chairman and CEO of celgene (currently a wholly-owned subsidiary of Bristol Myers Squibb) In his 16 years of work, Xinji has led the company to expand into a global pharmaceutical company, providing treatment solutions for patients with blood tumors, solid tumors and inflammatory diseases As a business leader, he is constantly entrusted with the task of leading the company to maintain the leading financial performance in the industry, leading the team to complete a number of multi billion dollar mergers and acquisitions of companies and products, establishing a rich drug product portfolio for the global market, and creating a potential cancer drug research and development pipeline The development of new base is obvious to all, and Bristol Myers Squibb has also recently completed the acquisition of new base of US $74 billion Mr alles's career spans the pharmaceutical industry for more than 30 years, and he has made outstanding contributions to patients around the world through medical innovation As an industry leader, Mr Alles has rich experience in operation, finance, business development and commercialization He is a former board member of the pharma, the European Federation of pharmaceutical industry associations (EFPIA), the biotechnology innovation organization of the United States (bio) and the Gilda club in New York, a non-profit organization that helps cancer families, and a former trustee committee member of the New Jersey Institute of health care (hinj) "Mr alles has a wide influence in the biomedical industry and is also an experienced board member He led Xinji from a U.S company with less than 500 people to a multinational company with 8800 employees serving patients in more than 50 countries around the world." Dr Mei Jianming, chairman and CEO of deqi pharmaceutical, said, "we are very pleased and welcome Mr alles to join the board of directors We believe that his joining will inject new impetus into the future development of the company, and will also bring the company a higher level of industry insight and strategic guidance Deqi has a solid R & D capability and is simultaneously improving its commercialization capability In the critical stage of accelerating expansion, Mr alles's outstanding leadership and rich business operation experience will have a significant impact on Deqi's global R & D and commercialization layout, including China and the Asia Pacific region " In addition to being the chairman and CEO of Xinji, Mr alles has served as a senior manager of many pharmaceutical companies in his 32 years of career He served as vice president of Aventis oncology, a pharmaceutical company of Aventis, and other important sales management positions of RH ô ne Poulenc Rorer (later merged into Aventis) He started his career in the pharmaceutical industry at Bayer and worked for centocor (later acquired by Johnson & Johnson) "Deqi pharmaceutical has grown rapidly into a biomedical company operating in both China and the United States, focusing on drug discovery, clinical research and commercialization of innovative cancer therapies." Mr alles said, "I'm very happy to join the board of directors of deqi, and I'm very looking forward to working with all directors and management teams to fulfill their responsibilities and promote this dynamic enterprise." Deqi Deqi Pharmaceutical Co., Ltd is a biomedical company operating in China and the United States It focuses on solving unmet clinical needs through new drug development, clinical research, drug production and marketing, and strives to provide the leading innovative anti-tumor therapy for patients in China, Asia and the world In April 2017, the global new drug leader Xinji (now formally acquired by Bristol Myers Squibb and merged into the world's fourth largest pharmaceutical company) became a long-term strategic partner of deqi pharmaceutical and invested in Deqi At present, Deqi pharmaceutical has six products in the clinical research and development stage: atg-010 (selinexor) combined with corticosteroid dexamethasone, which has been approved by the FDA of the United States to be listed on the market Currently, it is carrying out the registered clinical research on the treatment of adult patients with refractory and relapsed multiple myeloma in China The treatment scheme of the drug used to treat other multiple solid tumors and blood tumors has been promoted to clinical practice Later stage: atg-008 is a second-generation mTORC1 / 2 inhibitor, which is currently carrying out multi center clinical research on advanced liver cancer and other multiple tumors; atg-016 and atg-019 are two anti-tumor products in clinical 1 / 2 stage, which are in the process of including colorectal cancer, prostate cancer, non Hodgkin's lymphoma, myelodysplastic syndrome and other solid tumors, hematoma The clinical research of tumor; atg-527 is an antiviral product under research, and the clinical research of EBV (human herpesvirus type IV), RSV (respiratory syncytial virus) infection, CMV (cytomegalovirus) infection and other related diseases is under way; atg-017 is a highly selective small molecule inhibitor that acts on ERK1 / 2, and it is currently carrying out for a variety of solid tumors, non Hodgkin's lymphoma Clinical study of croma and acute myeloid leukemia In addition, Deqi pharmaceutical team is committed to the early preclinical development of several innovative target drugs in the fields of small molecules, monoclonal and bispecific antibodies Adorable adorable